Welcome to our dedicated page for Vitrolife news (Ticker: VTRLY), a resource for investors and traders seeking the latest updates and insights on Vitrolife stock.
The VTRLY news page tracks company communications and market-facing updates related to Vitrolife AB (publ), a biotechnology group active in reproductive health. Investors can use this feed to follow how the Vitrolife Group reports on its regional and product group performance, as well as strategic and financing developments that may influence the underlying business.
Vitrolife AB (publ) regularly publishes interim reports that detail sales in local currencies across EMEA, Americas and APAC, and across its Consumables, Technologies and Genetics product groups. These reports discuss organic growth excluding discontinued business, currency effects on sales and margins, gross margin levels, EBITDA, operating cash flow and net income. News items linked to these reports often include conference call invitations, where management presents the results and answers questions from investors, analysts and financial media.
The news flow also covers strategic initiatives and organisational changes. For example, Vitrolife AB (publ) has announced that it became a leading investor in AutoIVF, an early-stage MedTech company focused on making IVF more accessible, affordable and efficient through its OvaReady™ technology. The company has also communicated changes to its Executive Management Team, including the introduction of a SVP Innovation role to oversee R&D, Strategy & Sustainability, Portfolio Lifecycle Management and Market Access.
Governance and capital structure events appear in the form of Annual General Meeting notices and reports, which describe proposed and approved dividends, Board elections, auditor re-elections, share issue and share repurchase authorisations and share-based incentive programs. Financing news includes announcements such as the renewal and signing of a loan agreement comprising a term loan and revolving credit facility backed by Nordic banks.
By reviewing the VTRLY news feed, readers can follow how Vitrolife AB (publ) communicates on financial performance, IVF-related strategic investments, executive appointments, governance decisions and loan facilities. This makes the page a useful reference for anyone monitoring the company’s publicly disclosed developments over time.
Vitrolife AB has announced a share buyback program authorized by the Annual General Meeting on April 28, 2021. The program, aimed at securing obligations related to the LTIP 2021, will run from July 15 to August 31, 2021. Up to 52,568 shares can be repurchased at market prices, with payment in cash. Currently, Vitrolife does not hold any own shares.
Vitrolife invites stakeholders to a conference call discussing the interim report for January - June 2021, scheduled for July 15, 2021, at 10:00 a.m. CET. Registration will open 10-15 minutes prior to the call. Participants can dial in via the local Swedish number or the international line, using the conference ID 1295747. The interim report will be made available at 8:00 a.m. CET on the same day. A recorded version of the call will be accessible for seven days thereafter.
Vitrolife's Annual General Meeting on April 28, 2021, confirmed a dividend of SEK 0.80 per share for 2020, with a record date set for April 30, 2021. The meeting re-elected board members, including Jón Sigurdsson as Chairman, and approved total remuneration for the board amounting to SEK 2,165,000. The board received authorization to issue up to 10,850,000 shares and to repurchase shares not exceeding 10% of the total shares. Remuneration principles for senior management were also approved, including a share-based incentive program.
In its first quarter report for 2021, Vitrolife AB announced sales of SEK 379 million, a 14% increase compared to the previous year. In local currency, sales rose by 20%. The company's EBITDA reached SEK 163 million with a margin of 43%, impacted negatively by SEK 10 million due to exchange rate fluctuations. Net income increased to SEK 119 million, generating earnings per share of SEK 1.09.
Vitrolife AB has announced a conference call scheduled for April 22, 2021, at 10:00 a.m. CET, to discuss the interim report for January - March 2021. The call will be conducted in English, featuring CEO Thomas Axelsson and CFO Mikael Engblom. Registration is advised 10-15 minutes prior to the event, accessible via both local and international dial-in numbers. The interim report will be released at 8:00 a.m. CET on the same day. A recording of the conference will be available for seven days post-event.
Vitrolife has published its Annual Report for 2020, available for download on www.vitrolife.com. Printed versions will be mailed to requesting shareholders during the week of April 12. The report includes key financial data and insights, though specific performance metrics haven't been disclosed in this release. For further details, Mikael Engblom, the CFO, can be reached at +46 (0) 31 721 80 14. The release serves to keep shareholders informed about the company's performance and available resources.
Vitrolife AB (publ) has scheduled its Annual General Meeting for April 28, 2021, at 4:00 p.m., which will be conducted exclusively via postal voting due to health guidelines. To participate, shareholders must be registered by April 20, 2021, and submit their postal votes accordingly. Key proposals include a dividend of SEK 0.80 per share, unchanged Board remuneration of SEK 2,165,000, and authorizations for share issuance and buyback until the next AGM. The shareholders can review the full notice for more details.
The Election Committee of Vitrolife, appointed per the Annual General Meeting resolution on June 15, 2020, proposes key decisions for the upcoming AGM on April 28, 2021. The proposals include: Chairmanship by Patrik Tigerschiöld, a five-member Board, unchanged Board remuneration of SEK 2,165,000, re-election of current Board members, and the establishment of a new Election Committee for 2022. This information is disclosed in accordance with the Securities Markets Act.
Vitrolife AB reported a Q4 2020 sales figure of SEK 382 million, down 7% year-over-year. For the entire year, sales fell to SEK 1,246 million, a 16% decline. The company's EBITDA for Q4 increased to SEK 164 million, marking a 43% margin, while the annual EBITDA dropped to SEK 454 million with a 36% margin. Net income for Q4 was SEK 108 million, leading to earnings per share of SEK 0.99. A dividend of SEK 87 million was proposed. The company also faces a lawsuit over patent infringement.